Mechanisms involved in the evasion of the host defence by Pseudomonas aeruginosa.

Pseudomonas aeruginosa, an extracellular opportunistic pathogen, utilizes two major mechanisms to evade the host defence system. One of these mechanisms is the production of a large number of extracellular products, such as proteases, toxins, and lipases. The two proteases, alkaline protease and elastase, inhibit the function of the cells of the immune system (phagocytes, NK cells, T cells), inactivate several cytokines (IL-1, IL-2, IFN-r, TNF), cleave immunoglobulins and inactivate complement. Inhibition of the local immune response by bacterial proteases provides an environment for the colonization and establishment of chronic infection. The other mechanism by which P. aeruginosa evades the host defence system is the biofilm mode of growth of the bacteria in chronic infections. The biofilm-grown bacteria induce a low phagocyte response, and provide a barrier for the bacteria against antibodies, complement, and the cells of the immune system. Protection from the host defence system combined with increased antibiotic resistance of the bacteria in the biofilm are the major reasons for the persistence of P. aeruginosa in chronic infections.

[1]  D. Allison,et al.  Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? , 1988, The Journal of antimicrobial chemotherapy.

[2]  K. Miller,et al.  Elastase of Pseudomonas aeruginosa: Inactivation of Complement Components and Complement-Derived Chemotactic and Phagocytic Factors , 1974, Infection and immunity.

[3]  B. Pedersen,et al.  Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase , 1987, Infection and immunity.

[4]  M. Parmely,et al.  Inactivation of human gamma interferon by Pseudomonas aeruginosa proteases: elastase augments the effects of alkaline protease despite the presence of alpha 2-macroglobulin , 1989, Infection and Immunity.

[5]  J. Costerton,et al.  Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis , 1980, Infection and immunity.

[6]  K. Botzenhart,et al.  Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis , 1985, Infection and immunity.

[7]  B. Iglewski,et al.  Toxins of Pseudomonas aeruginosa: new perspectives. , 1983, Reviews of infectious diseases.

[8]  J. Costerton,et al.  Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm , 1991, Antimicrobial Agents and Chemotherapy.

[9]  J. A. Bass,et al.  Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. , 1978, The Journal of infectious diseases.

[10]  S. Carney,et al.  The invasion of burned skin by Pseudomonas aeruginosa , 1973, The British journal of dermatology.

[11]  M. Parmely,et al.  Antigenic specificities of Pseudomonas aeruginosa alkaline protease and elastase defined by human T cell clones. , 1986, Journal of immunology.

[12]  G. Pier,et al.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. , 1983, The Journal of infectious diseases.

[13]  D. Sordelli,et al.  Pulmonary Nonspecific Defense Mechanisms in Cystic Fibrosis: I. Phagocytic Capacity of Alveolar Macrophages and Neutrophils , 1980, Pediatric Research.

[14]  J. Costerton,et al.  Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa , 1990, Antimicrobial Agents and Chemotherapy.

[15]  J. Costerton,et al.  Bacterial biofilms in nature and disease. , 1987, Annual review of microbiology.

[16]  A. Kharazmi,et al.  Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence , 1984, Infection and immunity.

[17]  B. Tandler,et al.  Ultrastructure and Function of Alveolar Macrophages from Cystic Fibrosis Patients , 1980, Pediatric Research.

[18]  A. Kharazmi,et al.  Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro , 1984, Infection and immunity.

[19]  N. Høiby.  MICROBIOLOGY OF LUNG INFECTIONS IN CYSTIC FIBROSIS PATIENTS , 1982 .

[20]  D. Dearborn,et al.  Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. , 1989, The Journal of clinical investigation.

[21]  H. Tsuzuki,et al.  Protease and elastase of Pseudomonas aeruginosa: inactivation of human plasma alpha 1-proteinase inhibitor , 1979, Infection and immunity.

[22]  M. Parmely,et al.  Identification of the principal T lymphocyte-stimulating antigens of Pseudomonas aeruginosa , 1984, The Journal of experimental medicine.

[23]  D. Learn,et al.  Hypochlorite scavenging by Pseudomonas aeruginosa alginate , 1987, Infection and immunity.

[24]  A. Kharazmi,et al.  Inhibition of human monocyte chemotaxis and chemiluminescence by Pseudomonas aeruginosa elastase , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[25]  M. R. Brown,et al.  The influence of environment on envelope properties affecting survival of bacteria in infections. , 1985, Annual review of microbiology.

[26]  T. Theander,et al.  Selective Modulation of the CD4 Molecular Complex by Pseudomonas aeruginosa Alkaline Protease and Elastase , 1987, Scandinavian journal of immunology.

[27]  J. Costerton,et al.  Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms , 1990, Infection and immunity.

[28]  T. Theander,et al.  Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases , 1988, Infection and immunity.

[29]  R. Baltimore,et al.  Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains. , 1980, The Journal of infectious diseases.

[30]  S. Suter,et al.  Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. , 1984, The Journal of infectious diseases.

[31]  N. Høiby,et al.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis , 1983, Infection and Immunity.

[32]  A. Kharazmi,et al.  Demonstration of neutrophil chemotactic activity in the sputum of cystic fibrosis patients with Pseudomonas aeruginosa infection , 1986, European journal of clinical investigation.

[33]  G. Pier,et al.  In vitro T cell-mediated killing of Pseudomonas aeruginosa. II. The role of macrophages and T cell subsets in T cell killing. , 1985, Journal of immunology.

[34]  H. Stiver,et al.  Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. , 1988, Clinical and investigative medicine. Medecine clinique et experimentale.

[35]  A. Kharazmi,et al.  Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response , 1990, Infection and immunity.

[36]  R. Baltimore,et al.  IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. , 1985, The Journal of infectious diseases.

[37]  J. Powers,et al.  Pseudomonas aeruginosa elastase. Development of a new substrate, inhibitors, and an affinity ligand. , 1980, Journal of Biological Chemistry.